0
Orphan Designations
1
FDA Approvals
Latest: ILUVIEN (2014)
1
Active Trials
200 recruiting
2
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Alimera Sciences, Inc. is a company with 0 orphan drug designations across 2 rare diseases, including 1 FDA-approved therapy. Active clinical trials in 1 indication. 5 active policy bills affect their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cardiovascular disorder | - | Des.TrialAppr. |
| diabetes mellitus | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio
0% of portfolio targets high unmet need diseases
23
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
5
affecting portfolio